Project Grant R33AI101497

Shy Therapeutics, LLC received a $300,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 1, 2025, through August 31, 2027. The award supports the development of a novel class of antifungal small-molecule therapeutics designed to address the growing public health threat of drug-resistant fungal infections. The project will deliver research products including...

Federal Project Grant Award Summary The Food and Drug Administration (FDA) Research program (CFDA 93.103) awarded $5.17 million to the Icahn School of Medicine at Mount Sinai on September 25, 2025, to conduct a Phase 1/2 clinical trial investigating oral ciclopirox treatment for Congenital Erythropoietic Porphyria (CEP), an ultra-rare autosomal recessive genetic disorder. The research team, led by porphyria experts experienced in clinical trial execution, will evaluate the safety, efficacy,...

This $1 million cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a microbial discovery and biosynthesis platform for targeted protease inhibitors to treat COVID-19. Think Bioscience, Inc. will expand its demonstrated approach using microbial systems to guide the discovery and assembly of protease inhibitors. The company will generate new intellectual property covering the discovery platform and promising small molecules...

Federal Project Grant Award Summary Halomine Inc. (doing business as Avantguard) received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a novel, bio-inspired chloramine-based antifungal treatment for cutaneous fungal infections. The award, effective August 1, 2025 through July 31, 2026, supports the advancement of a stabilized chloramine polymer...

Federal Project Grant Award Summary Microbiotix, Inc. received a Project Grant award of $299,946 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by Mucorales fungi, a WHO high-priority...

The National Science Foundation Division of Chemistry awarded Clemson University a $492,000 Project Grant under the Mathematical and Physical Sciences federal grant program (CFDA 47.049) to study mechanisms of antifungal resistance. Professors Julia Brumaghim and Lukasz Kozubowski at Clemson University will investigate how azole antifungal compounds interact with metals like copper and iron to generate reactive oxygen species that damage fungal DNA and lead to chromosomal instability and drug...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on developing a novel drug candidate to treat demyelinating neuropathies. The $352,073 award will support rigorous in vivo testing of the experimental ABCA1 agonist drug, CS6253, in validated mouse models of hereditary peripheral nerve disorders characterized by impaired...

Federal Project Grant Award Summary Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, with completion targeted for August 31, 2027. The award supports the development of LP10581, a novel small-molecular-weight antifungal compound designed to address the critical public health challenge of drug-resistant fungal...

Federal Grant Award Summary Tarn Biosciences, Inc. received a $298,829 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 21, 2025, through July 31, 2027. The award supports the development of nitroreductase-activated inhibitor compounds, specifically a novel nitrofuran series represented by HC2210, for the treatment of mycobacterial infections including...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...